Transparency
Market Research Reports incorporated a definite business overview and
investigation inclines on “Lymphoblastic
Lymphoma Market”.
This report likewise incorporates more illumination about fundamental
review of the business including definitions, requisitions and
worldwide business sector industry structure. Lymphobalstic lymphoma
is also known as non-hodgkin lymphoma a type of cancer that primarily
affects lymphatic system. The lymphatic system comprises organs such
as the thymus, bone marrow, spleen, and the lymph nodes (or lymph
glands). Lymph nodes are connected by a network of tubes called
lymphatic vessels that contain lymph fluid and lymphatic tissue is
also found in other organs such as skin, lungs and stomach.
Prevalence of lymphoblastic lymphoma is high in teenagers and
children compared to adults. According to National Cancer Institute
(NCI), lymphoblastic lymphoma is the third most common childhood
malignancy, and lymphoblastic lymphoma accounts for approximately 7%
of cancers in children younger than 20 years. In the United States,
in 2013 about 800 new cases of lymphoblastic lymphoma are diagnosed
each year.
Browse
Full Report with TOC:
http://www.transparencymarketresearch.com/lymphoblastic-lymphoma-market.html
Lymphoblastic
lymphoma is an aggressive lymphoma. This means that it is
fast-growing and needs treatment straight away with chemotherapy. The
primary symptoms observed in lymphoblastic lymphoma are enlarged
lymph nodes, enlarged spleen, thrombocytopenia, fatigue, dyspnea and
others. The types of lymphoblastic lymphoma are overactive bladder
syndrome, chlamydia, cervical cancer, polycystic ovary syndrome
(PCOS), pelvic inflammatory diseases and others.
The
lymphoblastic lymphoma is diagnosed by removing enlarged lymph nodes
and examining with blood tests, x-rays and scans, lumbar puncture and
bone marrow. The first line of treatment for lymphoblastic lymphoma
consists of chemotherapy, radiotherapy, stem cell support and steroid
therapy. Chemotherapy is the main treatment for lymphoblastic
lymphoma usually treated more intensively than other types of
lymphomas. The patients are primarily referred to a specialist centre
for treatment and it is similar to the treatment for acute
lymphoblastic leukaemia. The three types of chemotherapies are used
against lymphoblastic lymphoma market such as induction chemotherapy,
consolidation therapy and continuing therapy. The potential
complications of lymphoblastic lymphoma include opportunistic
infections, neutropenic fever (admit the patient), bleeding, and
tumor lysis syndrome.
North
America was observed to be the largest market for lymphoblastic
lymphoma treatment and the major reasons behind this is the
increasing prevalence of genetic diseases and advanced diagnostic
facilities. In the U.S., the incidence of lymphoblastic lymphoma is
roughly 3000-3500 or approximately 1 in 50,000 in 2012. While
currently it has peak the incident rate of 2–5 years old,
decreasing in incidence with increasing age before increasing again
at around 50 years old. Lymphoblastic lymphoma is slightly more
common in males than females and an increased incidence in people
with a family history of autoimmune diseases, particularly autoimmune
thyroid diseases (namely Graves' disease or Hashimoto's thyroiditis).
Asia-Pacific were observed to be the most potential market as the
developing healthcare facilities and acceptance of modern technology
are enhancing the diagnostics of disease where the detection of
lymphoblastic lymphoma is easily observed. The high investments were
observed in the point of care sector of healthcare in the emerging
markets such as India, China, Brazil, Mexico and others that are
driving the market growth in these regions.
Some
of the key players in this market are Novartis AG, Pfizer Inc.,
Sanofi SA, Jazz Pharmaceuticals plc, Bristol-Myers Squibb Company,
AstraZeneca PLC, Eisai Inc., Amgen Inc. and BioCryst Pharmaceuticals,
Inc. Key players involved in the research and development are
National Cancer Institute, Fred Hutchinson Cancer Research Center,
The University of Texas M. D. Anderson Cancer Center, Memorial Sloan
Kettering Cancer Center , St. Jude Children's Research Hospital,
Inc., Johann Wolfgang Goethe University Hospitals and others.
Read
More Reports on Pharmaceuticals Markets:
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
This
research report analyzes this market depending on its market
segments, major geographies, and current market trends. Geographies
analyzed under this research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
This
report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This
report is a complete study of current trends in the market, industry
growth drivers, and restraints. It provides market projections for
the coming years. It includes analysis of recent developments in
technology, Porter’s five force model analysis and detailed
profiles of top industry players. The report also includes a review
of micro and macro factors essential for the existing market players
and new entrants along with detailed value chain analysis.
Enquiry
before Buying @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2924
About
Us
Transparency
Market Research is a market intelligence company providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers.
Followed
LinkedIn
:-https://www.linkedin.com/today/post/article/20140807051829-349336221-lymphoblastic-lymphoma-market-2014-2020
Contact:
Transparency
Market Research
90
State Street,
Suite
700,
Albany
NY — 12207
United
States
Tel:
+1-518-618-1030
USA — Canada
Toll Free 866-552-3453
Browse
Market Research Blogs:
0 comments:
Post a Comment